A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
Purpose
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome [ASyS]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Additional information can be found on https://myositis-study.com/.
Conditions
- Active Idiopathic Inflammatory Myopathy
- Myositis
- Dermatomyositis
- Polymyositis
- Immune-Mediated Necrotizing Myopathy
- Antisynthetase Syndrome
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Ability to consent in the jurisdiction in which the study is taking place and capable of giving signed informed consent. - A definite or probable clinical diagnosis of idiopathic inflammatory myopathy (IIM) - One of the following medical histories: Diagnosis of dermatomyositis (DM) or juvenile dermatomyositis (JDM), Diagnosis of polymyositis (PM) (including antisynthetase syndrome (ASyS)), Diagnosis of immune-mediated necrotizing myopathy (IMNM) - Diagnosed with active disease as defined by the presence of at least 1 of the following criteria: Abnormal levels of at least 1 of the following enzymes: creatine kinase (CK), aldolase, lactate dehydrogenase, aspartate aminotransaminase (AST), alanine aminotransferase (ALT), based on central laboratory results; Electromyography demonstrating active disease within the past 3 months; Active dermatomyositis (DM) skin rash; Muscle biopsy indicative of active idiopathic inflammatory myopathy (IIM) in the past 3 months; Magnetic resonance imaging within the past 3 months indicative of active inflammation - Muscle weakness - Receiving a permitted background treatment for idiopathic inflammatory myopathy. - Contraceptive use consistent with local regulations, where available, for individuals participating in clinical studies. Women of childbearing potential must have a negative serum pregnancy test during screening and a negative urine pregnancy test at baseline before receiving investigational medicinal product (IMP). The full list of inclusion criteria can be found in the protocol.
Exclusion Criteria
- A clinically significant active infection at screening - A COVID-19 polymerase chain reaction (PCR)-positive test before enrollment - Any other known autoimmune disease that, in the investigator's opinion, would interfere with an accurate assessment of clinical symptoms of idiopathic inflammatory myopathy (IIM) or put the patient at undue risk - A history of malignancy unless considered cured by adequate treatment, with no evidence of recurrence for ≥ 3 years before the first administration of the investigational medicinal product (IMP). Adequately treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer ; Carcinoma in situ of the cervix; Carcinoma in situ of the breast; Incidental histological finding of prostate cancer - Severe muscle damage - Glucocorticoid-induced myopathy that the investigator considers the primary cause of muscle weakness or permanent weakness linked to a non-idiopathic inflammatory myopathy (IIM) cause - Juvenile myositis (JDM) diagnosed > 5 years from screening or juvenile myositis with extensive calcinosis or severe calcinosis. - Uncontrolled interstitial lung disease or any other uncontrolled idiopathic inflammatory myopathy (IIM) manifestation that, in the opinion of the investigator, would be likely to require treatment with prohibited medication during the study - Other inflammatory and noninflammatory myopathies: inclusion body myositis, overlap myositis), metabolic myopathies, muscle dystrophies or a family history of muscle dystrophy, drug-induced or endocrine induced myositis, and juvenile myositis (other than juvenile dermatomyositis (JDM)) - Clinically significant disease, recent major surgery or intends to have surgery during the study, or has any other condition in the opinion of the investigator that could confound the results of the trial or put the patient at undue risk - Known hypersensitivity reaction to investigational medicinal product (IMP) or 1 of its excipients - Received a live or live-attenuated vaccine less than 4 weeks before screening. - Positive serum test at screening for active viral infection with any of the following conditions: Hepatitis B virus (HBV); Hepatitis C virus (HCV); HIV - Participant has previously participated in an efgartigimod clinical trial and received at least 1 dose of investigational medicinal product (IMP). - Participant is concurrently participating in any other clinical study, including a noninterventional study. - Participant has a current or history (ie, within 12 months of screening) of alcohol, drug, or medication abuse. - Participant is pregnant or lactating or intends to become pregnant during the study. - Participant has severe renal impairment . - Participant is institutionalized by a court or other governmental order or is in a dependent relationship with the sponsor or investigator. The full list of exclusion criteria can be found in the protocol.
Study Design
- Phase
- Phase 2/Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental EFG PH20 SC |
participants receiving efgartigimod PH20 SC on top of background treatment |
|
|
Placebo Comparator PBO PH20 SC |
participants receiving placebo PH20 SC on top of background treatment |
|
Recruiting Locations
Neuromuscular Research Center
Phoenix, Arizona 85028
Phoenix, Arizona 85028
HonorHealth Neurology - Bob Bove Neuroscience Institute - Neurology
Scottsdale, Arizona 85251
Scottsdale, Arizona 85251
Attune Health Research, Inc
Beverly Hills, California 90039
Beverly Hills, California 90039
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California 90033
Los Angeles, California 90033
Profound Research LLC - Oceanside
Oceanside, California 92056
Oceanside, California 92056
University of California, Irvine
Orange, California 92868
Orange, California 92868
Eisenhower Medical Center
Rancho Mirage, California 92270
Rancho Mirage, California 92270
Stanford Medicine Outpatient Center - Stanford Dermatology Clinic-Stanford University School of Medicine
Redwood City, California 94063-3132
Redwood City, California 94063-3132
California Pacific Medical Center - Sutter Health
San Francisco, California 94109
San Francisco, California 94109
Amyotrophic Lateral Sclerosis (ALS) Treatment Center,University of California San Francisco (UCSF)
San Francisco, California 94143-2202
San Francisco, California 94143-2202
Yale Cancer Center-Yale University School Of Medicine
New Haven, Connecticut 06520
New Haven, Connecticut 06520
Georgetown University Hospital
Washington, District of Columbia 20007
Washington, District of Columbia 20007
UF Health Rheumatology
Gainesville, Florida 32610-3008
Gainesville, Florida 32610-3008
Mayo Clinic
Jacksonville, Florida 32224
Jacksonville, Florida 32224
University of South Florida (USF) - Morsani Center (USF Health Carol and Frank Morsani Center for Advanced Healthcare)
Tampa, Florida 33616
Tampa, Florida 33616
Emory University Hospital, The Emory Clinic
Atlanta, Georgia 30322
Atlanta, Georgia 30322
Augusta University
Augusta, Georgia 30312
Augusta, Georgia 30312
Northwestern Memorial Hospital
Chicago, Illinois 60611
Chicago, Illinois 60611
University Of Kansas Medical Center
Kansas City, Kansas 66160
Kansas City, Kansas 66160
Johns Hopkins Medicine - Johns Hopkins Myositis Center
Baltimore, Maryland 21224
Baltimore, Maryland 21224
Harvard Medical School - Brigham and Women's Hospital (BWH) - The Schuster Family Transplantation Research Center (TRC)
Boston, Massachusetts 02115-6110
Boston, Massachusetts 02115-6110
Michigan State University - Neurology
East Lansing, Michigan 48824
East Lansing, Michigan 48824
St. Paul Rheumatology, PA
Saint Paul, Minnesota 55121
Saint Paul, Minnesota 55121
Northwell Health
Great Neck, New York 11021
Great Neck, New York 11021
Hospital for Special Surgery
New York, New York 10021
New York, New York 10021
University of North Carolina (UNC) School of Medicine
Chapel Hill, North Carolina 27514-4220
Chapel Hill, North Carolina 27514-4220
Carolina Arthritis Associates
Wilmington, North Carolina 28401
Wilmington, North Carolina 28401
Cleveland Clinic - Main Campus
Cleveland, Ohio 44195
Cleveland, Ohio 44195
The Ohio State University
Columbus, Ohio 43201
Columbus, Ohio 43201
Oregon Health and Science University
Portland, Oregon 97239
Portland, Oregon 97239
University of Pittsburg Medical Center
Pittsburgh, Pennsylvania 15261
Pittsburgh, Pennsylvania 15261
Vanderbilt University Medical Center (VUMC) - Vanderbilt Rheumatology Clinic
Nashville, Tennessee 37232-0028
Nashville, Tennessee 37232-0028
Austin Neuromuscular Center
Austin, Texas 78759
Austin, Texas 78759
McGovern Medical School -The University of Texas Health Science Center at Houston
Houston, Texas 77030
Houston, Texas 77030
Nerve And Muscle Center Of Texas
Houston, Texas 77030
Houston, Texas 77030
University of Vermont Medical Center - Main Campus
Burlington, Vermont 05401
Burlington, Vermont 05401
University of Washington Medical Center
Seattle, Washington 98195
Seattle, Washington 98195
More Details
- Status
- Recruiting
- Sponsor
- argenx